The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Sleep apnea is a condition where breathing repeatedly stops or reduces during sleep, often due to airway obstruction. It ...

Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the ...

Obstructive sleep apnea is still largely undiagnosed and untreated. In a growing marketplace of solutions, can negative pressure devices compete?

After announcing a $20 million funding round in June, the startup has set its sights on growing its customer-facing workforce ...

This can lead to delays in diagnosis as sleep apnea in women can be mistaken for anxiety, depression and menopause. As the signs are more subtle, research suggests as many as 90% of women who have ...

A new study found active-duty service members with sleep apnea face a greater risk of PTSD or a traumatic brain injury, ...

If left untreated, obstructive sleep apnea raises the risk of hypertension, heart disease, type 2 diabetes, depression and even an early death, according to the American Academy of Sleep Medicine.